Business Context and Reporting Period
Company: Park Ha Biological Technology Co., Ltd. (PHH)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended October 31, 2024
Business Overview: A Cayman Islands holding company operating in China through PRC subsidiaries. The company develops, manufactures, and sells skincare products under the "Park Ha" brand and operates a franchise model for beauty salons. Revenue is derived primarily from franchise fees and product sales to franchisees and non-franchisees.
Listing Status: Ordinary Shares listed on the Nasdaq Capital Market (Symbol: PHH) following an IPO in December 2024.
Key Financial Metrics
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue (Net) | $2,381,851 | $2,459,102 | $1,919,389 |
| Gross Profit | $2,186,515 | $2,148,113 | $1,410,227 |
| Gross Margin | 92% | 87% | 73% |
| Operating Income | $793,714 | $1,180,554 | $197,024 |
| Net Income | $478,561 | $852,042 | $191,298 |
| Cash and Cash Equivalents | $547,498 | $1,033,634 | $574,711 |
| Net Cash from Operating Activities | $960,470 | $126,537 | $1,442,306 |
| Total Assets | $3,083,283 | $2,264,867 | N/A |
| Total Liabilities | $1,577,198 | $1,252,394 | N/A |
Note: The filing text does not provide explicit debt figures other than operating lease liabilities ($70,318 total) and loans receivable from franchisees ($745,992 net). No long-term debt is reported.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 3% ($77,251) compared to FY 2023, primarily due to a decrease in franchise fees. Franchise fee revenue dropped from $1.81M to $1.67M, while product sales increased slightly by 9%.
- Profitability Drop: Net income decreased significantly by 44% ($373,481) to $478,561. This was driven by a 68% increase in General and Administrative (G&A) expenses, largely due to $278,698 in professional fees related to the completed audit and IPO services.
- Expense Increases: Selling and marketing expenses rose 21% due to increased payroll and bonuses. Allowance for expected credit losses increased 18% to $179,903, reflecting aging receivables and specific defaults from franchisees.
- Cash Position: Cash and cash equivalents decreased by 47% to $547,498, primarily due to net cash used in financing activities ($957,389) for deferred IPO costs and investing activities ($508,143) for loans to franchisees.
Guidance, Outlook, and Risks
Management Commentary & Outlook: The company plans to expand its franchise network and product lines, focusing on small molecule peptide hydration technology. Management intends to open vocational training schools and enhance social media marketing. However, the company currently intends to retain all earnings to support operations and does not expect to pay cash dividends in the foreseeable future.
Material Risks & Contingencies:
- Internal Control Weakness: Management concluded that internal controls over financial reporting were not effective as of October 31, 2024, due to insufficient in-house personnel with knowledge of U.S. GAAP and SEC reporting rules.
- Regulatory Risks (PRC): Significant risks exist regarding PRC government intervention, cybersecurity reviews (CAC), data privacy laws (PIPL), and the requirement to file with the CSRC for future overseas offerings. Failure to comply could result in fines or suspension of operations.
- HFCAA & Delisting: Trading on U.S. markets could be prohibited if the PCAOB is unable to inspect the company's auditor for two consecutive years under the Holding Foreign Companies Accountable Act.
- Concentration Risk: The company relies heavily on franchise fees (70% of revenue) and a limited number of suppliers. In FY 2024, four suppliers accounted for 47% of total purchases. Top five customers accounted for 38% of revenue.
- Franchisee Defaults: The company has recorded allowances for loans receivable from franchisees due to financial difficulties, with some payments aging over 1.5 years.
Investor Verification Checklist
- Internal Controls: Verify the remediation plan for the material weakness in internal controls over financial reporting.
- Revenue Quality: Assess the sustainability of franchise fee revenue given the decline in FY 2024 and the high concentration of revenue from a few franchisees.
- Receivables: Review the aging of accounts receivable and loans to franchisees, specifically the $46,362 fully impaired amount and other overdue payments.
- Regulatory Compliance: Confirm the status of CSRC filings and any ongoing cybersecurity reviews by the Cyberspace Administration of China (CAC).
- Supplier Concentration: Evaluate the risk of supply chain disruption given that four suppliers accounted for nearly half of total purchases in FY 2024.
- Post-IPO Liquidity: Monitor cash burn rates and the utilization of IPO proceeds ($4.8M gross proceeds) to ensure sufficient working capital for expansion.